Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (≥ 60 years) with active myeloid malignancies

被引：39

作者：

Spyridonidis, A ^{[1
]}

Bertz, H ^{[1
]}

Ihorst, G ^{[1
]}

Grüllich, C ^{[1
]}

Finke, J ^{[1
]}

机构：

[1] Univ Freiburg, Med Ctr, D-79106 Freiburg, Germany

来源：

BLOOD | 2005年 / 105卷 / 10期

关键词：

D O I：

10.1182/blood-2005-01-0196

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4147 / 4148

页数：2

共 7 条

[1] Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia [J].

Bertz, H ;

Potthoff, K ;

Finke, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1480-1484

[2] Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen [J].

Chakraverty, R ;

Peggs, K ;

Chopra, R ;

Milligan, DW ;

Kottaridis, PD ;

Verfuerth, S ;

Geary, J ;

Thuraisundaram, D ;

Branson, K ;

Chakrabarti, S ;

Mahendra, P ;

Craddock, C ;

Parker, A ;

Hunter, A ;

Hale, G ;

Waldmann, H ;

Williams, CD ;

Yong, K ;

Linch, DC ;

Goldstone, AH ;

Mackinnon, S .

BLOOD, 2002, 99 (03) :1071-1078

[3] Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS [J].

de Lima, M ;

Couriel, D ;

Thall, PF ;

Wang, XM ;

Madden, T ;

Jones, R ;

Shpall, EJ ;

Shahjahan, M ;

Pierre, B ;

Giralt, S ;

Korbling, M ;

Russell, JA ;

Champlin, RE ;

Andersson, BS .

BLOOD, 2004, 104 (03) :857-864

[4] Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning [J].

Ho, AYL ;

Pagliuca, A ;

Kenyon, M ;

Parker, JE ;

Mijovic, A ;

Devereux, S ;

Mufti, GJ .

BLOOD, 2004, 104 (06) :1616-1623

[5] HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies [J].

Maris, MB ;

Niederwieser, D ;

Sandmaier, BM ;

Storer, B ;

Stuart, M ;

Maloney, D ;

Petersdorf, E ;

McSweeney, P ;

Pulsipher, M ;

Woolfrey, A ;

Chauncey, T ;

Agura, E ;

Heimfeld, S ;

Slattery, J ;

Hegenbart, U ;

Anasetti, C ;

Blume, K ;

Storb, R .

BLOOD, 2003, 102 (06) :2021-2030

[6] Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation [J].

Pérez-Simón, JA ;

Díez-Campelo, M ;

Martino, R ;

Sureda, A ;

Caballero, D ;

Cañizo, C ;

Brunet, S ;

Altes, A ;

Vazquez, L ;

Sierra, J ;

San Miguel, JF .

BLOOD, 2003, 102 (03) :1108-1113

[7] Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years [J].

Wong, R ;

Giralt, SA ;

Martin, T ;

Couriel, DR ;

Anagnostopoulos, A ;

Hosing, C ;

Andersson, BS ;

Cano, P ;

Shahjahan, M ;

Ippoliti, C ;

Estey, EH ;

McMannis, J ;

Gajewski, JL ;

Champlin, RE ;

De Lima, M .

BLOOD, 2003, 102 (08) :3052-3059

← 1 →